Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Mutagenesis ; 27(6): 731-5, 2012 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22874647

RESUMO

Circulating unconjugated bilirubin (UCB) has been reported to protect against lung and colorectal cancer. The present study aimed to explore, for the first time, whether mildly elevated circulating UCB, as found in Gilbert`s syndrome (GS), is associated with changes of DNA damage. A random 76 individuals, matched for age and gender, were recruited from the general population and allocated into the GS group (UCB ≥ 17.1 µM; n = 38) or control group (UCB <17.1 µM; n = 38). Chromosomal and cytological changes were determined in lymphocytes and buccal cells using the cytokinesis-block micronucleus cytome assay (CBMN) and buccal micronucleus cytome assay (BMcyt). No significant differences were found between GS subjects and the control group in the CBMN and BMcyt determined endpoints. Subsequently, when age dependency of effects were analysed, lower formation of buccal micronucleated cells (by 73.3%) and buccal nuclear buds (by 70.9%) in the GS subgroup ≥ 30 years were found, compared to the GS subgroup <30 years. These findings suggest DNA protection in epithelial tissue of older individuals with GS.


Assuntos
Bilirrubina/sangue , Aberrações Cromossômicas , Ensaio Cometa/métodos , Doença de Gilbert/genética , Testes para Micronúcleos/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Bilirrubina/efeitos adversos , Neoplasias Colorretais/patologia , Citocinese , Dano ao DNA , Determinação de Ponto Final , Feminino , Ácido Fólico/sangue , Doença de Gilbert/sangue , Homocisteína/sangue , Humanos , Neoplasias Pulmonares/patologia , Linfócitos/patologia , Masculino , Pessoa de Meia-Idade , Vitamina B 12/sangue , Adulto Jovem
2.
Br J Pharmacol ; 161(8): 1751-62, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20718734

RESUMO

BACKGROUND AND PURPOSE: Haem oxygenase 1 (HO-1) is an inducible protein that plays a major protective role in conditions such as ischaemia-reperfusion injury and inflammation. In this study, we have investigated the role of haem arginate (HA) in human male subjects in the modulation of HO-1 expression and its correlation with the GT length polymorphism (GT(n)) in the promoter of the HO-1 gene. EXPERIMENTAL APPROACH: In a dose-escalation, randomized, placebo-controlled trial, seven healthy male subjects with a homozygous short (S/S) and eight with a long (L/L) GT(n) genotype received intravenous HA. HO-1 protein expression and mRNA levels in peripheral blood monocytes, bilirubin, haptoglobin, haemopexin and haem levels were analysed over a 48 h observation period. KEY RESULTS: We found that the baseline mRNA levels of HO-1 were higher in L/L subjects, while protein levels were higher in S/S subjects. HA induced a dose-dependent increase in the baseline corrected area under the curve values of HO-1 mRNA and protein over 48 h. The response of HO-1 mRNA was more pronounced in L/L subjects but the protein level was similar across the groups. CONCLUSIONS AND IMPLICATION: HA is an effective inducer of HO-1 in humans irrespective of the GT(n) genotype. The potential therapeutic application of HA needs to be evaluated in clinical trials.


Assuntos
Arginina/farmacologia , Heme Oxigenase-1/biossíntese , Heme/farmacologia , Adulto , Arginina/administração & dosagem , Arginina/efeitos adversos , Bilirrubina/sangue , Relação Dose-Resposta a Droga , Indução Enzimática , Haptoglobinas/metabolismo , Heme/administração & dosagem , Heme/efeitos adversos , Heme/metabolismo , Heme Oxigenase-1/sangue , Heme Oxigenase-1/genética , Hemopexina/metabolismo , Homozigoto , Humanos , Infusões Intravenosas , Masculino , Polimorfismo Genético
3.
Eur J Clin Invest ; 37(10): 820-5, 2007 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17764464

RESUMO

BACKGROUND: The increasingly recognized prognostic impact of the strong ion gap in critical illness is in contrast to its largely unknown chemical nature. Experimental and clinical evidence suggest that acute phase proteins might account for elevation of the strong ion gap. The hypothesis of this investigation was that acute phase proteins account for strong ion gap in critically ill patients. MATERIALS AND METHODS: The charges of the two acute phase proteins C-reactive protein and fibrinogen were estimated by a computer model. Additionally, 142 patients admitted to a medical intensive care unit of a university hospital were studied prospectively during a six month period. Serial daily observations were recorded and classified according to the systemic inflammatory state. The acute phase proteins C-reactive protein and fibrinogen were measured and the strong ion gap was calculated from the measured acid-base variables. RESULTS: The approximated mean charges of C-reactive protein and fibrinogen at a pH of 7.4 are -4.0 and -13.6 per molecule, respectively. Therefore, their negative charge is too small to explain the elevated strong ion gap even during a substantial increase of C-reactive protein and fibrinogen due to an acute-phase reaction. Moreover, C-reactive protein did not correlate with the strong ion gap when partialized for creatinine (R = 0.02, P = 0.567). Fibrinogen did not correlate with the strong ion gap. Creatinine correlated with the strong ion gap (R = 0.42, P < 0.001). Neither systemic inflammatory state nor increasing C-reactive protein levels were associated with an increasing strong ion gap. CONCLUSION: Acute phase proteins do not account for an elevated strong ion gap in critically ill patients.


Assuntos
Equilíbrio Ácido-Base , Ânions/análise , Gasometria/métodos , Proteína C-Reativa/análise , Fibrinogênio/análise , Concentração de Íons de Hidrogênio , Desequilíbrio Ácido-Base/sangue , Adulto , Idoso , Ânions/sangue , Dióxido de Carbono/sangue , Simulação por Computador , Estado Terminal , Interpretação Estatística de Dados , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Estudos Prospectivos
4.
Eur J Clin Invest ; 37(8): 665-72, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17635578

RESUMO

BACKGROUND: Pituitary adenylate cyclase activating polypeptide 1-38 (PACAP38) displays biological activities (e.g. bronchodilatory, pulmonary vasodilatory and anti-inflammatory properties) that are relevant in several pulmonary diseases. The aim of this study was to assess the safety and tolerability and the pulmonary and systemic effects of inhaled PACAP38 in humans. MATERIALS AND METHODS: Twelve healthy male subjects (mean age 28) were studied in a randomized, double-blind, placebo-controlled dose escalation trial with inhalation of PACAP38 to a cumulative dose of 480 microg. Lung function was measured by body plethysmography. Systemic absorption was evaluated by plasma levels, skin blood flux (estimated by laser Doppler imager fluxmetry) and systemic haemodynamics. RESULTS: Inhalation of PACAP38 did not cause relevant adverse reactions or an increase of PACAP38 plasma levels. No statistically significant changes in lung function tests and no systemic effects (blood pressure, pulse rate or skin blood flux) occurred. CONCLUSION: Inhaled PACAP38 was well tolerated without systemic side-effects in healthy male subjects.


Assuntos
Pressão Sanguínea/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Polipeptídeo Hipofisário Ativador de Adenilato Ciclase/efeitos adversos , Fluxo Sanguíneo Regional/efeitos dos fármacos , Respiração/efeitos dos fármacos , Vasodilatadores/efeitos adversos , Administração por Inalação , Adulto , Método Duplo-Cego , Humanos , Masculino , Polipeptídeo Hipofisário Ativador de Adenilato Ciclase/administração & dosagem , Testes de Função Respiratória/métodos , Pele/irrigação sanguínea , Pele/efeitos dos fármacos , Vasodilatadores/administração & dosagem
5.
Anaesthesia ; 59(11): 1111-5, 2004 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-15479321

RESUMO

Alterations of electrolytes and albumin cause metabolic acid-base disorders. It is unclear, however, to what degree these plasma components affect the overall metabolic acid-base state in the course of critical illness. We performed serial analyses of the metabolic acid-base state in 30 critically ill patients over the course of 1 week. We applied a physical-chemical acid-base model and used a linear regression model to determine the influence of sodium, chloride, unmeasured anions and albumin on the net metabolic acid-base state. Progressive hypochloraemia was identified as the main cause of developing metabolic alkalosis. Changes in serum chloride and unmeasured anions were responsible for changes of 41% and 22% in the metabolic acid-base state, respectively. Sodium and albumin played a minor role. In conclusion, chloride is the major determinant of metabolic acid-base state in critical illness.


Assuntos
Desequilíbrio Ácido-Base/sangue , Cloretos/sangue , Estado Terminal , Alcalose/sangue , Feminino , Humanos , Modelos Lineares , Masculino , Estudos Prospectivos , Albumina Sérica/metabolismo , Sódio/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...